XenoPort to Present at the RBC Capital Markets’ Global Healthcare Conference

  XenoPort to Present at the RBC Capital Markets’ Global Healthcare Conference  2014 RBC Capital Markets' Global Healthcare Conference  Business Wire  SANTA CLARA, Calif. -- February 18, 2014  XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the RBC Capital Markets’ Global Healthcare Conference. The live presentation will occur at 11:35 a.m. Pacific Time (2:35 p.m. Eastern Time) on Tuesday, February 25, 2014. A replay of the presentation will also be available.  To access the live presentation via the Web, please go to www.XenoPort.com. Please connect to the Web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.  A replay of the Webcast can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation.  About XenoPort  XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT^® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for psoriasis and/or relapsing forms of multiple sclerosis. REGNITE^® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease. To learn more about XenoPort, please visit the Web site at  www.XenoPort.com.  HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.  XNPT2G  Contact:  XenoPort, Inc. Jackie Cossmon, 408-616-7220 ir@XenoPort.com